Institute of Organic Chemistry and Biochemistry AS CR, V.v.i., Flemingovo Nam. 2, 166 10, Prague 6, Czech Republic.
Institute of Organic Chemistry and Biochemistry AS CR, V.v.i., Flemingovo Nam. 2, 166 10, Prague 6, Czech Republic.
Antiviral Res. 2020 Oct;182:104899. doi: 10.1016/j.antiviral.2020.104899. Epub 2020 Aug 5.
Remdesivir was shown to inhibit RNA-dependent RNA-polymerases (RdRp) from distinct viral families such as from Filoviridae (Ebola) and Coronaviridae (SARS-CoV, SARS-CoV-2, MERS). In this study, we tested the ability of remdesivir to inhibit RdRps from the Flaviviridae family. Instead of remdesivir, we used the active species that is produced in cells from remdesivir, the appropriate triphosphate, which could be directly tested in vitro using recombinant flaviviral polymerases. Our results show that remdesivir can efficiently inhibit RdRps from viruses causing severe illnesses such as Yellow fever, West Nile fever, Japanese and Tick-borne encephalitis, Zika and Dengue. Taken together, this study demonstrates that remdesivir or its derivatives have the potential to become a broad-spectrum antiviral agent effective against many RNA viruses.
瑞德西韦已被证明可抑制来自不同病毒家族的 RNA 依赖性 RNA 聚合酶（RdRp），例如丝状病毒科（埃博拉病毒）和冠状病毒科（SARS-CoV、SARS-CoV-2、MERS）。在这项研究中，我们测试了瑞德西韦抑制黄病毒科 RdRp 的能力。我们使用的是瑞德西韦在细胞中产生的活性物质，即适当的三磷酸酯，可直接使用重组黄病毒聚合酶在体外进行测试。我们的结果表明，瑞德西韦可有效抑制引起严重疾病的病毒的 RdRp，如黄热病、西尼罗河热、日本脑炎和蜱传脑炎、寨卡病毒和登革热。总之，这项研究表明，瑞德西韦或其衍生物有可能成为一种广谱抗病毒药物，对许多 RNA 病毒有效。
